Potent P2Y12 inhibitors versus clopidogrel in high ischemic and low bleeding risk patients undergoing percutaneous coronary intervention for chronic coronary syndromes
Event: EAPCI Summit 2026
Topic: Pharmacotherapy
Session: Tailoring antithrombotic therapy after PCI: balancing ischaemic and bleeding risks
